Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
AVITA MEDICAL INC (AVH)ASX AI Signals has generated 3 signal for AVH during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest AVH Signals | |
| 25/05/2026 | BUY |
| 24/05/2026 | BUY |
| 23/05/2026 | BUY |
AVH Share Price | |
| Current Price | $1.395 |
| 52 Week High | $1.930 |
| 52 Week Low: | $1.005 |
| Trading at (% of 52 Week High) | 72.28% |
Avita Medical Inc (ASX: AVH) is a regenerative medicine company that develops and markets innovative wound care and skin regeneration products. Its flagship technology, ReCell®, is used for treating burns and other skin injuries by enabling the regeneration of healthy skin from a small sample of the patient’s own cells. The company operates globally, providing solutions for medical professionals and patients.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY signal for AVITA MEDICAL INC at the current price of 1.25 reflects moderate confidence based on recent positive momentum and sector potential. However, the stock's volatility and limited market capitalization introduce notable risk.
Key Insights
Institutions' substantial holdings in AVITA Medical implies that they have significant influence over the company's share price The top 25 shareholders own 49% of the company Recent purchases by insiders
A look at the shareholders of AVITA Medical, Inc. (NASDAQ:RCEL) can tell us which AVITA Medical
VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered i AVITA Medical
VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced preliminary unau AVITA Medical
VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executiv AVITA Medical
VALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shaLatest AVITA MEDICAL INC(AVH) News
Institutional investors own a significant stake of 48% in AVITA Medical, Inc. (NASDAQ:RCEL)
AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AVITA Medical to Host Investor Webinar Briefing
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial